In November 2023, the US Food and Drug Administration did something it had never done before. It accepted that old age could be the target of a drug.

Not a disease of old age, not arthritis, kidney failure or cognitive decline. Ageing itself, as the thing to be treated. The drug in question was for large dogs, and the company behind it was a San Francisco startup called Loyal. Two years on, a second Loyal drug is two-thirds of the way through the paperwork that would put it on the American market: a daily flavoured tablet for senior dogs of almost any size, called LOY-002.

If you have an old dog, you have probably already done the arithmetic on whether they will still be here when it arrives. So let's be straight about it.

The short answer: No date exists, because the process that would put LOY-002 in an Australian vet clinic has not started. LOY-002 is not registered in Australia, no application has been made to the APVMA, and Loyal has never publicly mentioned Australia. Realistically that means the back half of this decade at the earliest, and it is not guaranteed to happen at all.

What Loyal is actually trying to do

The interesting thing about LOY-002 is not that it is a longevity drug. It is what it is mimicking.

In 1987, researchers at Nestlé Purina took 48 Labrador puppies from seven litters, paired them off, and fed one dog in each pair 25% less than its litter-mate had eaten the day before. Same food, less of it, for life. Then they waited until every dog had died.

The lean dogs lived a median 13.0 years. Their litter-mates managed 11.2. More striking than the extra 1.8 years was when things started going wrong: median age at the first radiographic sign of hip arthritis was six years in the well-fed dogs and twelve in the lean ones. Half a lifetime's difference in when the decline set in.

Read the design carefully, though, because it is routinely misreported as an argument for feeding dogs less than normal. The restricted dogs finished at a body condition score of 4.6 out of 9, ideal, or a shade lean. The control dogs, fed to appetite until they were three, finished at 6.7, which is overweight. So the study is much closer to evidence that avoiding overweight extends life than that eating below normal does. It is also one breed, in one research colony, run by a pet food company that publicises it as its own work.

Even with those caveats, it stands alone. It remains the only randomised trial in dogs, of any intervention, with lifespan as the endpoint. And it is the intellectual ancestor of LOY-002. Loyal describes its drug as "a practical alternative to established longevity interventions like caloric restriction", a way to get some of what those Labradors got, without asking owners to keep a dog slightly hungry for fifteen years.

What the drug does, on Loyal's account, is metabolic. As dogs age, insulin rises and insulin sensitivity falls, and the company's thesis is that this metabolic drift is one of the engines of age-related disease. LOY-002 is intended to improve insulin sensitivity and lower insulin.

The molecule itself has not been disclosed. That is ordinary for a drug at this stage rather than evasive, Loyal says it will release the details closer to launch, and there is a commercial logic to holding back. A good deal of longevity pharmacology involves using known compounds in new ways, which means the patent protection sits in the method rather than the molecule: the dose, the formulation, the species, the biomarkers used to decide who gets treated. Name the compound early and you weaken the thing you are protecting.

That dosn't make it a black box though, Loyal holds a granted US patent, "Method of increasing lifespan in mammals", covering the use of PPAR-gamma agonists,. a class that includes the human diabetes drug pioglitazone, to treat age-related metabolic dysfunction, with claims tied to markers including fasting insulin, triglycerides and adiponectin. That does not tell you LOY-002 is pioglitazone. It could be a different agonist in the class, a reformulation, or something adjacent. But it tells you the neighbourhood, and the neighbourhood is insulin sensitisation, which is precisely what you would expect of a drug built to imitate those Labradors.

It is a prescription daily tablet for dogs aged ten and over weighing at least 6.4kg: which is to say most senior dogs, not a niche. And it is being tested at a scale veterinary medicine has never attempted: 1,300 dogs across 70 American clinics, placebo-controlled and blinded, running roughly four years. Loyal calls it the largest clinical trial in the history of veterinary medicine, and as far as we can establish that is a fact rather than a flourish. The first dog was dosed in December 2023. Enrolment closed in July 2025.

Is LOY-002 approved? Not quite, and the distinction matters

Loyal is not going for full approval. It is going for FDA Expanded Conditional Approval, a pathway that lets a drug reach the market on a lower evidence bar while the sponsor keeps collecting data — designed for exactly this situation, where the definitive trial takes years and the animals waiting cannot.

Three technical sections have to be accepted before Loyal can even apply. Two are in.

Here is the sentence worth holding on to. On the FDA's own definition, conditional approval means a sponsor has shown "a reasonable expectation of effectiveness" but "has not yet proven that it meets the substantial evidence standard". Translated: the FDA has agreed that LOY-002 is likely to work and appears safe. It has not agreed that it works. That is what the four-year trial is for, and the trial has not reported.

On safety, what Loyal has disclosed is a study at one, three and five times the intended dose with no clinically significant adverse events, plus field data from more than 400 dogs dosed for up to a year. The underlying data is not published; the company says it is limited in what it can share before approval.

One more note, and it is less a criticism of Loyal than an observation about how this story has travelled. Every milestone above comes from a Loyal announcement. There is no FDA press release about LOY-002, no named FDA statement, and no Loyal entry in the Green Book of approved animal drugs. The facts look sound. But when you read that "the FDA agrees", the source is the company.

And if you have read that LOY-002 was arriving in 2026, a lot of coverage said so, including a Forbes cover story — that is out of date. Loyal's own statements in January and February 2026 pushed the application itself to 2027.

Why an American approval doesn't reach an Australian dog

Medicines do not cross borders the way products do. There is no version of this where the FDA signs off and Australian vets start writing scripts.

Veterinary medicines here are registered by the Australian Pesticides and Veterinary Medicines Authority under the Agvet Code, and the APVMA assesses independently every time. There is no mutual recognition of American veterinary approvals. The only formal instrument between the two agencies is a confidentiality commitment signed in 2005, which lets them share information, not decisions.

The APVMA does share the work with other regulators. It runs joint veterinary drug reviews with New Zealand and Health Canada, and a simultaneous review arrangement with the UK. The FDA is in none of them. So the one regulator that will have looked hardest at LOY-002 is the one Australia has no work-sharing arrangement with.

Overseas data still helps. The APVMA accepts scientific assessments from regulators it trusts, including American ones, and says this may reduce both timeframes and fees. In practice, for a drug like this, the saving is mostly financial. In the APVMA's own worked example, a complete overseas dossier cuts the chemistry assessment from 13 months to six, but another module, poisons scheduling, takes 13 months regardless, and that is the one setting the pace.

There is a harder problem, and we will flag it as our reading rather than a regulator's position. An FDA conditional approval is built on an explicitly incomplete efficacy package. The APVMA's efficacy guidance asks for trials producing clinically relevant, statistically significant results. We could find no APVMA statement either permitting or prohibiting registration off a conditional approval, the question appears never to have arisen. But on the face of that guidance, the trigger for an Australian application is probably not the American conditional approval at all. It is the four-year trial reporting, and full US approval after it.

The timeline, once someone actually starts

Assume Loyal or an Australian licensee lodges an application tomorrow. The APVMA publishes its assessment periods module by module, and for a daily oral drug for dogs the longest applicable module runs 13 months, with three more to finalise.

On our reading of those published figures, that is roughly 16 months, closer to 23 if the APVMA comes back with questions, which it often does. Two details are easy to miss. The clock does not start when the paperwork is lodged; it starts when the application passes an initial check. And preparing the dossier happens before any of that, as would any Australian confirmatory trial the APVMA decided to ask for. For a drug whose endpoint is lifespan, that last possibility is not a small thing.

Has Loyal said anything about Australia?

We went looking, and it is not there.

No Loyal statement about any market outside the United States. Not Australia, and not the EU, the UK, Canada, Japan or New Zealand. No "global launch" language anywhere in their materials. Every open regulatory role on their careers page is US-based, and there is no VP of Global Regulatory Affairs or equivalent, in animal health, that is the hire that tells you a company has started thinking internationally. The trial is described as running "across the United States". The $100m they raised in February 2026 names no launch geography at all, not even America. There is no Loyal entry in PubCRIS, the APVMA's register.

None of which means Australia will never happen. Companies expand. It means nothing has started, and that anyone telling you otherwise is guessing.

The median is about ten months, and the median is misleading, because the distribution has two humps rather than a middle. Drugs a company prioritises for Australia land inside a year, or arrive here first, or nearly eight months ahead of the Americans. Drugs a company does not prioritise arrive four or five years late. Or never: three of the comparators we checked have never been registered here at all. Entyce, after more than a decade. Bexacat, after nearly four years.

And Laverdia-CA1, which is the one to watch. It is the closest thing to a real comparator that exists, a conditionally approved companion animal drug that has since run the full course to full American approval. Conditional approval in January 2021, full approval in December 2025. Five and a half years of being sold in the United States. Never registered in Australia.

So the variable is not how fast the APVMA moves. It is whether a company decides Australia is worth the dossier. That distinction is worth holding, because "Australian red tape" is the lazy explanation and the evidence does not support it: Stelfonta was invented and sponsored in Australia, and still cleared the EU, the UK, Switzerland and the FDA before it cleared the APVMA.

Could an Australian dog get it sooner?

Not lawfully, and we would steer you firmly away from the workarounds that circulate online.

Owners cannot import it. Under the Agricultural and Veterinary Chemicals (Administration) Act 1992, importing an unregistered chemical product without a reasonable excuse or written APVMA consent is an offence, and the APVMA is unambiguous that it "does not issue Import Consents for unregistered products intended for private use", even where a product looks much like something already sold here.

A vet can apply for a Consent to Import a product for use under prescription, and that pathway is real. It is also narrow. Consent cannot be granted after the fact, applications go in at least ten business days before arrival, and state law varies more than most people expect, the New South Wales guidance we reviewed, which self-dates to 2012 and may since have been superseded, restricts fairly tightly what unregistered products a vet may supply for a companion animal. Any vet weighing this up would want current advice for their own state.

The permit routes mostly do not fit. The APVMA classes dogs as a major species, so a senior dog product is not a minor use. Emergency permits are built around disease outbreaks, and ageing is not an outbreak. So lets all work together to bring it here the right way.

So what is the honest answer?

Three things have to happen, in order, and only the first is underway.

LOY-002 has to reach the American market: close, but not there. Loyal or an Australian licensee has to apply to the APVMA: no evidence anyone has. And the APVMA has to assess and register it: roughly 16 to 23 months once it begins.

Layer on the likelihood that the real trigger is the four-year trial reporting rather than the conditional approval, and the honest answer is the back half of this decade at the earliest, with a genuine possibility it does not happen here at all, exactly as it has not for Laverdia.

That is a hard answer to sit with if your dog is twelve. Which brings us to the part of this that is actually within reach.

The thing the drug is copying is available now

Go back to those Labradors, because there is a neat logic in it.

LOY-002 exists because keeping dogs lean works, and asking owners to do it for fifteen years mostly does not. The drug is an attempt to get the benefit without the discipline. But the benefit itself is not waiting on a regulator. It is on your kitchen floor.

The population data supports the trial. A retrospective analysis of 50,787 neutered dogs across roughly 900 American hospitals found overweight body condition associated with significantly higher mortality, with hazard ratios above two in several smaller breeds and median lifespan reductions running from five months to two and a half years depending on breed and sex. Be careful with those top-end figures, they are the largest of twenty-four strata, and for large breeds the number is closer to six to eight months. The study is associational, and several authors were employed by Mars-owned WALTHAM or Banfield. It points the same way regardless.

Australia has a problem here, and an evidence gap. The last comparable survey, in 2005, found 41% of 2,661 dogs across 52 practices were overweight or obese. That is a twenty-year-old figure from a survey with a 24.9% response rate, and nothing newer exists. Which is its own quiet indictment.

Beyond body condition, the evidence thins, and we would rather say so than dress it up.

Dental disease is strongly and dose-dependently associated with kidney disease: in a Banfield-funded cohort of 329,412 dogs, hazard ratios for incident azotaemic chronic kidney disease climbed with periodontal stage from 1.8 to 2.7. What has never been shown is that treating it changes organ outcomes or lifespan, a 2023 review of 36 studies found not one with a systemic or survival endpoint. Brushing daily or every other day is the only home measure with a demonstrated effect on plaque and gingivitis. Good reason to do it. Not a basis for claiming it protects the kidneys.

Senior screening reliably finds things. In a prospective study of 122 apparently healthy senior dogs, 20% were diagnosed with something at baseline, and 47% of the malignancies picked up over two years were found on physical examination alone. Another study of 45 senior dogs recorded 353 abnormal findings, 7.8 per dog, with 80% having at least one previously unrecognised problem. Whether finding things earlier makes dogs live longer has never been tested in a controlled trial — the current senior care guidelines describe themselves as evidence-guided rather than evidence-based. Screening remains the most sensible thing available. Just know what it is.

And the rest is thinner still. Exercise has no canine study with lifespan as an outcome. Neuter timing is genuinely contested, including Australian data on Rottweilers pointing the opposite way to the international picture.

What this means for dog longevity

Set Australia aside for a moment, because the more interesting thing is happening either way.

Until three years ago, ageing was not something you could get a drug approved for. Regulators approve treatments for diseases, and being old is not a disease, no diagnostic code, no clean endpoint, no obvious trial design. What the FDA did in November 2023 was concede that a drug could be developed and approved to extend lifespan. That is the actual precedent, and it is bigger than any single tablet.

Dogs got there before humans, and will probably keep getting there first. They age the way we do but faster. They live in our houses, breathe our air, share our sofas and increasingly our waistlines. A four-year trial in dogs answers a question that would take forty years in people, which is why canine longevity has quietly become one of the most useful research settings in ageing biology rather than a curiosity at the edge of it.

What follows is a category, not a product. Loyal has three drugs across two mechanisms. The Dog Aging Project is running a rapamycin lifespan trial, TRIAD, powered to detect a 6% difference across 580 dogs and concluding in 2029. Rapamycin already holds a conditional FDA approval in cats, for a heart condition. Some of this will fail. That is what a functioning research field looks like from the inside.

The part that gets less attention is the problem a longevity drug creates and cannot solve. A drug aimed at ageing needs someone to answer three questions before it is any use: which dogs are ageing badly, when to start, and whether it is working. None of those are pharmacology. They are measurement. Population trials tell you a drug works on average across 1,300 dogs; they tell you nothing about the one asleep at your feet.

Where Elita fits

We've built a longevity platform, so people reasonably ask whether a drug like this competes with what we do. It does not. It is the other half of the same problem.

Loyal is building a pharmacological intervention on a single mechanism, being validated against a population-level lifespan endpoint over four years. We are building the individual-level picture: biological data, clinical history and what an owner actually notices, tracked over time on one dog, so decline gets caught early and decisions get made on evidence instead of instinct.

If and when a drug like LOY-002 reaches Australia, the dogs who benefit most will be the ones whose owners already have a baseline to compare against. In the meantime, the levers with real evidence behind them are the ones worth pulling. So make sure you're set up on Elita Blueprint well before it hits our shores.

We will keep this page current

This is our regulatory status tracker for LOY-002 in Australia, and we maintain it. We will update it when Loyal submits its manufacturing section, when it applies for conditional approval, if an application appears in APVMA PubCRIS, when the four-year trial reports, or if Loyal says anything at all about Australia.

Last updated 3 August 2026. Nothing has been announced by Loyal since 11 February 2026.

Frequently asked questions

Is LOY-002 available in Australia?
‍No. LOY-002 is not registered with the APVMA, cannot be prescribed as a registered product in Australia, and cannot lawfully be imported by an owner. No application has been made.

Is LOY-002 FDA approved?
No. Loyal is pursuing FDA Expanded Conditional Approval and has had two of three required technical sections accepted. The third, manufacturing, had not been submitted as of Loyal's February 2026 statement, and Loyal expects to apply for conditional approval in 2027.

When will LOY-002 be available in Australia?No date can be given, because no APVMA application exists. Once one is lodged, our reading of published APVMA assessment timeframes suggests roughly 16 to 23 months. Realistically the back half of this decade at the earliest, and it is not certain to happen.

Will Australia automatically approve LOY-002 once the FDA does?
‍No. There is no mutual recognition of US veterinary approvals. The APVMA assesses independently, and the FDA is not a participant in the APVMA's international work-sharing programmes.

Can I import LOY-002 for my dog?
‍No. Importing an unregistered veterinary chemical product without APVMA consent is an offence, and the APVMA does not issue import consents for private use.

Could my Australian vet prescribe it?
‍Not currently. LOY-002 is not on the market anywhere in the world, so there is nothing to import. Once a product is registered overseas, a vet can apply to the APVMA for a Consent to Import for use under prescription, but that pathway is narrow and state prescribing law varies significantly.

What does LOY-002 actually do?On Loyal's account, it targets age-related metabolic dysfunction by improving insulin sensitivity and lowering insulin. It is a daily prescription tablet for dogs aged ten and over weighing at least 6.4kg.

What is in LOY-002?
‍Loyal has not disclosed the active ingredient, which is normal for a drug pre-approval and protects a method-of-use patent position. Loyal's granted US patent covering the senior dog programme concerns PPAR-gamma agonists, a class of insulin-sensitising drugs that includes pioglitazone. That indicates the drug class rather than confirming the compound.

Is LOY-002 the same as rapamycin?
‍No. Different compounds, different mechanisms. Rapamycin has no published lifespan data in dogs, and the only regulatory approval for it in a companion animal is in cats, for a heart condition.

Is there anything available in Australia now that extends a dog's life?
‍Keeping a dog lean rather than overweight is the only intervention shown in a randomised trial with lifespan as the endpoint to extend canine lifespan. Everything else currently available is associational or measured on surrogate endpoints.

Sources

Loyal company statements: LOY-002 safety milestone, 13 January 2026 · LOY-002 RXE, 26 February 2025 · Series C, 11 February 2026 · For dog owners · Clinical trials · What is FDA conditional approval? · The Purina study

Patents: US 12,161,636 B2, "Method of increasing lifespan in mammals" (granted 10 December 2024) · WO2024263787A1, methods for measuring metabolic dysfunction

FDA: Conditional Approval Explained · Green Book recent approvals · APVMA–FDA confidentiality commitment

APVMA: Timeframes and fees · Registering a new veterinary product with a new active constituent · International and other national assessments · Veterinary drug joint reviews · Efficacy and target animal safety guideline · Types of permits · Consent to import · PubCRIS

Studies: Kealy 2002, JAVMA 10.2460/javma.2002.220.1315 · Lawler 2008, Br J Nutr 10.1017/S0007114507871686 · Smith 2006, JAVMA 10.2460/javma.229.5.690 · Salt 2019, JVIM 10.1111/jvim.15367 · McGreevy 2005, Vet Rec 10.1136/vr.156.22.695 · Glickman 2011, Prev Vet Med 10.1016/j.prevetmed.2011.01.011 · Barbosa 2023, Res Vet Sci 10.1016/j.rvsc.2022.10.025 · Harvey 2015, J Vet Dent 10.1177/089875641503200102 · Marynissen 2025, JVIM 10.1111/jvim.70166 · Davies 2012, JSAP 10.1111/j.1748-5827.2012.01247.x · Joonè 2023, Sci Rep 10.1038/s41598-023-45128-w · Coleman 2025 (TRIAD protocol), GeroScience 10.1007/s11357-024-01484-7

‍